English 
Celaid Therapeutics Inc. announced that it successfully completed the first close of its Series B financing. It raised JPY 1.055 billion, which is about USD 7.2 million. This funding came from venture capital firms and the Japan Agency for Medical Research and Development (AMED). Celaid has raised a total of JPY 2.52 billion (USD 17.14 million), including grants and subsidies.
The funding shows increasing confidence in Celaid’s main program, CLD-001. This is an innovative therapy using ex vivo-expanded hematopoietic stem cells (HSCs) for severe pediatric non-malignant diseases. CLD-001 shows good promise in preclinical models. It has effective safety and notable advancements in cell manufacturing and CMC. The company is advancing toward a U.S. FDA pre IND filing.
Celaid is also developing its proprietary HSC expansion platform through collaborations, including with AGC Inc., to expand and evaluate induced pluripotent stem cell–derived HSPCs. This platform is under active assessment by global pharmaceutical and biotech partners.
こちらもお読みください： Hinge Bio partners with Kyorin to Develop HB2198 in Japan
The newly raised capital will fund GMP manufacturing and non clinical studies to support CLD 001’s planned clinical trials in the U.S. It will also strengthen Celaid’s HSC expansion capabilities and broaden applications in cell and gene therapy, positioning the company as a leader in regenerative medicine innovation.
日本語